Court to rule in case pitting brand-name drugmaker against generics

04/14/2005 | Wall Street Journal, The

A court in Indianapolis is expected to issue a ruling today in a drug-patent case that could have a major impact on the way potential investors view the stock of innovative drugmakers versus those that make generics. The court is set to rule at the end of the day on whether Eli Lilly's Zyprexa for treating schizophrenia and bipolar disorder is protected by a valid patent through 2011 or whether Zenith Goldline Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical Industries were correct in asserting the drug's patent is invalid.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA